UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $27.90 Million Stake in Halozyme Therapeutics, Inc. $HALO

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 32.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 356,472 shares of the biopharmaceutical company’s stock after selling 171,559 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Halozyme Therapeutics were worth $27,901,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Measured Wealth Private Client Group LLC raised its holdings in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 124 shares during the last quarter. Larson Financial Group LLC boosted its stake in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the last quarter. MidFirst Bank acquired a new position in Halozyme Therapeutics during the 2nd quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Halozyme Therapeutics during the 2nd quarter worth approximately $28,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Halozyme Therapeutics in the second quarter worth approximately $30,000. 97.79% of the stock is owned by institutional investors.

Insider Activity at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares of the company’s stock, valued at $1,084,650. The trade was a 33.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the sale, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 32,478 shares of company stock worth $3,076,604. 2.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Friday, August 7th. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. TD Cowen lifted their price target on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $115.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Stock Up 1.0%

HALO stock opened at $110.76 on Friday. The stock has a fifty day moving average of $90.05 and a 200-day moving average of $75.58. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $111.15. The company has a market capitalization of $12.57 billion, a price-to-earnings ratio of 33.06, a PEG ratio of 0.43 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. The business had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company’s revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.98 earnings per share for the current year.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Broad upward revisions to earnings forecasts: Zacks Research raised its FY2026 EPS estimate to $8.24 from $7.56, above the $7.75 consensus, and increased its FY2027 estimate to $9.01 from $8.96. It also lifted estimates for Q4 2026, Q1 2027, Q4 2027, Q1 2028, and Q2 2028. The revisions reinforce expectations for continued earnings growth at Halozyme. MarketBeat Halozyme estimates
• Positive Sentiment: Analyst maintains Buy rating and raises valuation target: HC Wainwright reaffirmed its Buy rating and set a $115 price target, implying additional upside from the recent trading level. Benzinga analyst update
• Positive Sentiment: Stock reaches a new one-year high: The milestone reflects strong investor momentum and growing confidence in Halozyme’s commercial and earnings outlook. Halozyme reaches new one-year high
• Neutral Sentiment: Upcoming investor conferences: CEO Helen Torley and CFO Darren Snellgrove are scheduled to participate in conferences and meet with investors. The events could provide updates on ENHANZE and Halozyme’s broader drug-delivery portfolio, but no new financial guidance was announced. Halozyme investor conferences announcement
• Negative Sentiment: Some longer-term estimates were reduced: Zacks lowered its Q3 2027 EPS forecast to $2.16 from $2.26 and FY2028 EPS to $10.06 from $10.21. These modest cuts partially offset the broader set of upward revisions, though the estimates still imply substantial future earnings growth.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.